drugset
drugset / Trial / NCT06831136

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136 ↗

Phase 2 Recruiting 24 enrolled The University of Texas Health Science Center, Houston
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

Timeline

Start
2025-03-26
Primary completion
2028-01-20
Completion
2030-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 400 mg —
Background Capecitabine Small molecule — —
Background Cisplatin Other / unclassified — —
Background Gemcitabine Small molecule — —
Background Nab-paclitaxel Small molecule — —

Indications

pancreatic ductal adenocarcinoma